Favorable outcomes of NPM1mut AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance

Bibliographic Details
Main Authors:	I. Khan, A. Kaempf, S. Raghuwanshi, M. Chesnokov, X. Zhang, Z. Wang, A. Domling, J. W. Tyner, C. Camacho, A. L. Gartel
Format:	Article
Language:	English
Published:	Nature Publishing Group 2023-08-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-023-00898-4

Internet